The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical ...
In einem turbulenten Marktumfeld hat die Aktie von Mainz Biomed (NASDAQ: MYNZ) BV ein 52-Wochen-Tief erreicht und ist auf 6,12 US-Dollar gesunken. Das für innovative Krebsscreening-Technologien bekann ...
Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
Benzinga Finance on MSN12d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Mainz Biomed Announces Stock Split. BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Sonstiges Mainz Biomed gibt Aktienzusammenlegung bekannt 29.11.2024 / 14:45 CET/CEST Für den Inhalt der Mitteilung ...
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback